News

Corbus to Present Promising Data on Resunab as Systemic Sclerosis Treatment

Corbus Pharmaceuticals will present results showing that Resunab (JBT-101), the company’s cannabis-derived treatment for systemic sclerosis (SSc), can trigger specific molecular pathways which resolve inflammation and halt fibrosis. The data will be presented by Michael L. Whitfield, PhD, a molecular biology professor at Dartmouth and scientific founder of Celdara Medical,…

IVIG Therapy for Systemic Sclerosis Is Safe, Improves Organ Function, Study Finds

A new study from France found that treatment with intravenous immunoglobulins (IVIG), known to have anti-fibrotic activity, is effective in improving muscle, joint and digestive tract function in patients with systemic sclerosis (SSc). The study, “Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients…

Immunosuppressants Only of ‘Weak’ Benefit to Diffuse Scleroderma Patients, Study Reports

A large study following patients in the early stages of diffuse cutaneous scleroderma showed that immunosuppressants offered only a negligible benefit for those who took them, compared to those who didn’t. Since immunosuppressants produced numerically larger reductions in skin symptoms, the findings may support patients using such drugs from the onset of their…

Many Scleroderma Patients Were Exposed to Heavy Metals, Study Finds

Researchers have found links between several heavy metals and scleroderma, a discovery that prompted them to encourage doctors to check whether their patients had occupational exposure to heavy metals. Interestingly, some metals were associated more with male scleroderma patients and some with females. The study, “Systemic sclerosis and…